Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma

다국어 초록 (Multilingual Abstract)

To investigate the therapeutic potential of the next‐generation anti‐CD37 radioimmunoconjugate 177Lu‐lilotomab satetraxetan (177Lu‐lilotomab) in combination with the anti‐CD20 antibody rituximab for treatment of mice with non‐Hodgkin's lymphoma (NHL) xenografts.
Nude mice with subcutaneous (s.c.) Burkitt's lymphoma Daudi xenografts and SCID mice intravenously (i.v.) injected with Mantle cell lymphoma Rec‐1 cells were treated with either 177Lu‐lilotomab or rituximab alone or with the combination of both treatments. Tumour volume, body weight, blood counts and clinical status were monitored. CD20 expression was measured using flow cytometry with fluorescence‐labelled rituximab.
The combination of 177Lu‐lilotomab and rituximab was synergistic for treatment of nude mice with s.c. Daudi xenografts while it was additive for treatment of SCID mice with i.v. injected Rec‐1 cells. Binding of rituximab to NHL cells in‐vitro was increased by pretreatment with 177Lu‐lilotomab.
Treatment of mice with NHL xenografts with 177Lu‐lilotomab synergistically increased tumour suppression of subsequent anti‐CD20 immunotherapy and improved survival. If the same effect is confirmed in a recently started clinical study, it could change the way radioimmunotherapy and CD20 immunotherapy would be used in the future.